# A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

> **NCT07334496** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Gan & Lee Pharmaceuticals.** · enrollment: 198 (estimated)

## Conditions studied

- Biosimilarity

## Interventions

- **DRUG:** GLR1044 injection
- **DRUG:** Dupilumab Injection

## Key facts

- **NCT ID:** NCT07334496
- **Lead sponsor:** Gan & Lee Pharmaceuticals.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-07-17
- **Final completion:** 2026-07-17
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07334496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07334496, "A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07334496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*